AptarGroup reports Q2 adjusted EPS $1.37, consensus $1.36

Reports Q2 revenue $910.06M, consensus $933.17M. “Strong sales growth in our Pharma business and broad-based margin expansion helped us achieve another quarter of strong EPS growth. Our proprietary drug delivery systems continue to see healthy demand, sales for our active material science technologies grew nicely in the quarter and volumes for consumer dispensing solutions continued to progressively improve in North America. For the first six months of the year, we achieved double-digit earnings growth and delivered strong net cash provided by operations,” said CEO Stephan Tanda.